|
|
Article: Aviva Raises $11.8M In Series B To Push Biochip Technology.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
To help along its partnership with Axon Instruments Inc., Aviva Biosciences Corp. conducted the first closing of a Series B financing that raised $11.8 million.
"The money's in the bank," said Eric Lachenmeier, director of business development for San Diego-based Aviva.
That brings the total raised by privately held Aviva since 1999 to $16.8 million. The round was led by longstanding investor China Development Industrial Bank, of Taiwan, and included new investor Pac-Link Management Corp., also of Taiwan.
Another new investor is Axon, of Union City, Calif., which is developing a line of automated ion channel drug ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|